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Influenza virus infection in travelers to tropical and subtropical
countries
Abstract
BACKGROUND: Influenza outbreaks have been reported among travelers, but attack rates and
incidence are unknown. METHODS: A cohort study was conducted. Travelers to subtropical and
tropical countries recruited at the University of Zurich Travel Clinic (Switzerland), January 1998 to
March 2000, were investigated with pre- and posttravel assessment of hemagglutination inhibition and
by questionnaire. RESULTS: Among 1450 travelers recruited who completed questionnaires and
provided serum samples before departure, 289 (19.9%) reported febrile illness during or after traveling
abroad; of these, 211 (73.0%) provided paired serum samples. Additionally, paired serum samples were
collected from 321 frequency-matched afebrile control subjects among the remaining 1161 subjects of
the study population. Seroconversion for influenza virus infection was demonstrated in 40 (2.8%) of all
travelers; 18 participants (1.2%) had a > or = 4-fold increase in antibody titers. This corresponds to an
incidence of 1.0 influenza-associated events per 100 person-months abroad. Among the 211 febrile
participants, 27 (12.8%) had seroconversion, 13 (6.2%) with a > or = 4-fold increase; among the 321
afebrile control subjects, 13 (4.0%) had seroconversion, 5 (1.6%) with a > or = 4-fold increase.
Twenty-five seroconverters (62.5%; P = .747) acquired influenza outside of the European epidemic
season. Sixteen patients (40.0%) sought medical attention either abroad or at home, and 32 (80.0%)
were asymptomatic at the time of completion of the survey. CONCLUSIONS: This survey indicates that
influenza is the most frequent vaccine-preventable infection among travelers to subtropical and tropical
countries. Infections occur mainly outside the domestic epidemic season, and they have a considerable
impact. Pretravel vaccination should be considered for travelers to subtropical and tropical countries.
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Background. Influenza outbreaks have been reported among travelers, but attack rates and incidence are
unknown.
Methods. A cohort study was conducted. Travelers to subtropical and tropical countries recruited at the
University of Zurich Travel Clinic (Switzerland), January 1998 to March 2000, were investigated with pre- and
posttravel assessment of hemagglutination inhibition and by questionnaire.
Results. Among 1450 travelers recruited who completed questionnaires and provided serum samples before
departure, 289 (19.9%) reported febrile illness during or after traveling abroad; of these, 211 (73.0%) provided paired
serum samples. Additionally, paired serum samples were collected from 321 frequency-matched afebrile control subjects
among the remaining 1161 subjects of the study population. Seroconversion for influenza virus infection was dem-
onstrated in 40 (2.8%) of all travelers; 18 participants (1.2%) had a4-fold increase in antibody titers. This corresponds
to an incidence of 1.0 influenza-associated events per 100 person-months abroad. Among the 211 febrile participants,
27 (12.8%) had seroconversion, 13 (6.2%) with a4-fold increase; among the 321 afebrile control subjects, 13 (4.0%)
had seroconversion, 5 (1.6%) with a4-fold increase. Twenty-five seroconverters (62.5%; ) acquired influenzaPp .747
outside of the European epidemic season. Sixteen patients (40.0%) sought medical attention either abroad or at
home, and 32 (80.0%) were asymptomatic at the time of completion of the survey.
Conclusions. This survey indicates that influenza is the most frequent vaccine-preventable infection among
travelers to subtropical and tropical countries. Infections occur mainly outside the domestic epidemic season, and
they have a considerable impact. Pretravel vaccination should be considered for travelers to subtropical and tropical
countries.
Epidemiological investigations of health risks in trav-
elers have thus far concentrated on infections perceived
as specific for this population, such as travelers’ diar-
rhea, malaria, hepatitis, and other travel-related vac-
cine-preventable diseases. Hepatitis A appeared to be
the most common vaccine-preventable infection [1–4].
Earlier reports indicate that fever, often of undeter-
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mined origin, affects 11% of travelers while abroad [5].
Anecdotal reports of outbreaks of influenza associated
with travel by air or ship, also reported after military
exercises abroad, indicate that international travelers
are at risk of acquiring this infection [6–11].
Posttravel monitoring of hospital admissions iden-
tified respiratory tract infections, including influenza,
as a common cause of illness in returned travelers, but
thus far, the attack rate and incidence of influenza in
travelers have not been assessed [12–14]. Thus, we per-
formed a seroepidemiological cohort study to deter-
mine the attack rate and incidence of influenza virus
infection among Swiss residents traveling to subtropical
and tropical countries, the proportion of symptomatic
and asymptomatic cases, and geographic areas and sea-
sons with particular risk.
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METHODS
Participants. After receipt of approval by our institutional
ethics committee, persons aged 12 years who attended the
University of Zurich Travel Clinic (Switzerland) were invited
from 1 January 1998 to 31 March 2000 to participate in the
study if they were planning travel to subtropical and tropical
countries for6 months, had not traveled to these destinations
during the preceding 2 months, reported no febrile illness at
the date of enrollment, were able to understand a written
German-language questionnaire, and resided in German-speak-
ing Switzerland. They were selected regardless of their vacci-
nation status against influenza, and each participant received
travel advice in accordance with World Health Organization
(WHO) recommendations of that time [15].
Recruited volunteers were then invited to sign a written in-
formed consent form and to provide demographic (i.e., age,
sex, place of residence, and date of enrollment) and basic travel
data (i.e., travel destinations and dates and duration of stay),
as well as a first blood sample. To include a posttravel follow-
up time, a structured questionnaire was mailed to the volun-
teers 2 weeks after their return, followed by a reminder, if
necessary. They were asked to report travel history, type of
travel, visits to health care providers, fever and other health
problems, impact of illness on travel plans, and their actual
health status. Those who had experienced a “febrile illness”
(measured temperature or just subjective fever) were invited to
return to our travel clinic to provide a second blood sample.
Additionally, a control sample from members of the same study
population who did not experience fever abroad was frequency-
matched with samples from those with fever by travel region
and travel season and was similarly followed up.
Serological testing and case definitions. Paired serum sam-
ples were collected at intervals of 3 weeks but 50 weeks
and were analyzed together for antibodies to influenza A virus
subtypes H1N1 and H3N2 and for influenza B virus by the
hemagglutination inhibition assay (HI) [16]. Selection of con-
temporary reference strains was based on data from global
influenza surveillance [17–19]. Serum samples were tested in
2 batches. The first batch consisted of samples collected from
1 January to 16 October 1998, with use of reference strains and
antibodies against A/Bayern/7/95 (H1N1), A/Beijing/262/
95(H1N1), A/Wuhan/359/95(H3N2), A/Sydney/5/97(H3N2),
B/Beijing/184/93, and B/Shandong/7/97. The second batch con-
sisted of samples collected subsequently until 31 March 2000,
with use of reference strains and antibodies against A/Bayern/
7/95(H1N1), A/New Caledonia/20/99(H1N1), A/Sydney/5/
97(H3N2), A/Nanchang/933/95(H3N2), B/Yamanashi/166/98,
and B/Shandong/7/97. Because we did not expect acute influ-
enza, no virus isolation or PCR was done on respiratory tract
specimens.
Confirmed cases of influenza virus infection were defined by
a 4-fold increase above pretravel titer, and probable cases of
influenza were defined by a 2.0- to 3.9-fold increase in serum
antibody titer, compared with the first sample. Because we were
interested in determining the ratio of clinically apparent to
inapparent infections on the basis of the HI assay, no clinical
symptoms of influenza-like illness were included in the case
definitions. To avoid a misclassification of influenza virus in-
fections, cases for which pretravel or posttravel blood sampling
intervals exceeded 30 days and, at the same time, occurred
during the northern epidemic season (December–March) were
excluded (17 cases total). Probable cases of influenza were in-
cluded to avoid the loss of potential cases due to such factors
as asymptomatic infection or repeated exposure.
Travelers with pretravel HI antibody titers of 1:20 for all
3 subtypes included in the then-contemporary vaccine of the
Northern Hemisphere were considered to be immune against
the corresponding vaccine strains and were termed immune.
No influenza vaccine history was established, but at that time,
neither we in Switzerland nor others specifically recommended
this vaccine to travelers.
Statistical analysis. Data were analyzed with Stata statis-
tical software, version 7 (Stata). Statistical significance for the
crude analysis of the independent variables assessed by the
questionnaires was determined by 2-sided x2 and Fisher’s exact
tests and by logistic regression with calculation of risk ratios
and 95% confidence intervals. All covariates with a P value of
!.1 at the univariate analysis were included in multivariate
logistic regression analyses. We checked for confounding and
colinearity whenever the b estimate or the standard error were
disparate for the crude and adjusted OR estimate. To assess
potential classification biases, sensitivity analyses were done to
compare the population who provided paired serum samples
with the residual study population, as well as to compare con-
firmed influenza virus infections with probable ones.
RESULTS
Overall, 1999 persons were recruited, of whom 506 (25.3%)
did not provide an informed consent or were lost to follow-
up; 43 (2.2%) did not correspond to the inclusion and exclusion
criteria. Thus, a total of 1450 travelers (738 men [50.9%] and
712 women [49.1%]) completed questionnaires and provided
a serum sample before departure. They had a median age of
31 years (range, 12–83 years); 54 (3.7%) were aged 65 years.
Both sexes had a comparable age distribution. As presented in
table 1, the median duration of travel was 21 days (range, 7–
182 days). Among 289 persons (19.9%) who reported febrile
illness during or after traveling abroad, 211 provided second
serum samples; additionally, 321 control subjects without fever
provided a second serum sample. Among the total of 532 vol-
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Table 1. Demographic characteristics of the total population in a study of influenza among Swiss















Age, median years (range) 29 (20–68) 34 (22–59) 31 (20–72) 31 (12–83)
Sex, percentage of female / male subjects 44/56 36/64 52/48 49/51
Travel destination, no. (%) of subjects
Africa 5 (27.8) 6 (27.3) 7 (10.9) 447 (30.8)
Asia excluding India 7 (38.9) 4 (18.2) 18 (28.1) 436 (30.1)
Indian subcontinent 2 (11.1) 6 (27.3) 7 (10.9) 130 (9.0)
Latin America 4 (22.2) 6 (27.3) 21 (32.8) 393 (27.1)
Otherb 0 (0) 0 (0) 1 (1.6) 44 (3.0)
Duration of stay, median days (range) 28 (14–168) 28 (14–168) 25 (7–175) 21 (7–182)
a Subjects with pretravel hemagglutination inhibition antibody titers of 1:20 for all 3 subtypes included in the then-
contemporary vaccine of the Northern Hemisphere were considered to be immune against the corresponding vaccine
strains.
b The Middle East and the Caribbean.
Table 2. Factors associated with detecting influenza virus in-
fections in travelers.
Type of analysis, risk factor Odds ratio (95% CI) P
Univariate analysis
Sex, female / male 0.68 (0.36–1.30) .244
Age, by decade 0.95 (0.74–1.21) .651
Travel destination
Hemisphere, Northern / Southern 0.95 (0.51–1.79) .886
Africa 0.85 (0.42–1.71) .640
Asia 1.28 (0.70–0.35) .422
Indian subcontinent 2.61 (1.18–5.79) .018
Southeast Asia 0.98 (0.46–2.09) .965
Latin America 0.85 (0.41–1.77) .672
Travel duration of 128 days 1.46 (0.72–2.95) .297
Type of travel, individual / with others 1.76 (0.92–3.37) .086
Season of travel, Dec–Mar / Apr–Nov 0.92 (0.48–1.77) .808
Year of travel, 1998 / 1999 1.09 (0.54–2.17) .817
Multivariate analysis
Sex, female / male 0.70 (0.36–1.34) .280
Age, by decade 1.01 (0.77–1.31) .956
Indian subcontinent 2.76 (1.24–6.16) .013
Type of travel 1.93 (0.95–3.92) .067
NOTE. Multivariate analysis corresponds to multivariate logistic regres-
sion analyses.
unteers with 2 samples, the median interval between collection
of the first and second serum specimen was 109 days (range,
31–331 days).
Overall, 40 travelers tested positive for influenza virus in-
fection. Infections were rated as confirmed for 18 subjects
(45.0%) and as probable for 22 subjects (55.0%); 27 (67.5%;
14 men and 13 women) had reported fever episodes while
abroad or shortly after return, whereas 13 (32.5%) remained
asymptomatic throughout (10 men and 3 women). Thus, sub-
jective fever was significantly associated with influenza virus
infection ( ), and symptomatic patients reported visitsP ! .001
to health care practitioners more frequently than did asymp-
tomatic patients ( ); there were no significant differencesP ! .001
between them with regard to demographic or travel charac-
teristics. The median age of the 40 subjects who tested positive
by HI was 33 years (range, 20–68 years), and the age distri-
butions were slightly different between men and women (table
1). The largest proportion (26 [65.0%] of 40 cases) of influenza
virus infections occurred in travelers aged 20–39 years (Pp
)..818
The total attack rate was 2.8% for all travelers in the study,
and it was 1.2% when only confirmed influenza virus infections
were taken into account. The incidences were 2.3 influenza-
associated events per 100 person-months abroad for all influ-
enza infections and 1.0 for those with confirmed infections.
Among the 532 subjects who underwent serological analysis,
64 (12.0%) were classified as immune. A minority of subjects
in this group had fever.
Influenza virus infections were acquired during travel to Asia
(47.5%), Africa (27.5%), and Latin America (25.0%); this re-
flects the distribution of destinations among all travelers en-
rolled in the study—that is, 39.1%, 30.8%, and 27.1%, re-
spectively ( ). Participants visiting the IndianPp .626
subcontinent were more often affected (table 2). None of the
other variables tested, such as demographic data and travel
characteristics, were associated with a significantly increased
risk of acquiring influenza virus infection. Additionally, there
was no indication that persons with preexisting illness were
more often affected.
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A (H1N1) 2 (11.1) 1 (4.5) … …
A (H3N2) 14 (77.8) 16 (72.7) … …
B 0 (0) 3 (13.6) … …
A or Bb 2 (11.1) 2 (9.1) … …
Symptom
Fever
Subjective 13 (72.2) 14 (63.6) 21 (32.8) 289 (19.9)
Temperature of 38C 9 (50.0) 9 (40.9) 8 (12.5) 154 (10.6)
Sore throat and/or cough 13 (72.2) 11 (50.0) 22 (34.4) 249 (17.2)
Achesc 11 (61.1) 13 (59.1) 30 (46.9) 455 (31.4)
No fever 5 (27.8) 8 (36.4) 43 (67.2) 1161 (80.1)
a Subjects with pretravel hemagglutination inhibition antibody titers of 1:20 for all 3 subtypes
included in the then-contemporary vaccine of the Northern Hemisphere were considered to be immune
against the corresponding vaccine strains.
b Four persons tested positive for 11 influenza virus subtype.
c Headache, myalgia, and/or arthralgia; multiple answers were possible.
The most frequent symptoms included subjective fever, re-
spiratory symptoms (such as sore throat or cough), diarrhea,
headache, and myalgia (table 3). Exanthema, arthralgia, coryza,
fatigue, and otitis media were reported less frequently. Only
57.4% of those with fever had measured their temperature; the
median temperature reported was 38.5C (range, 37.5C–
40.5C). Influenza A (H3N2) virus was the most commonly
detected subtype, followed by influenza A (H1N1) virus and,
less frequently, influenza B virus. Four (10.0%) of the 40 trav-
elers with positive HI results tested positive for 11 influenza
virus subtype. Fifteen travelers (37.5%) acquired influenza virus
infection during the main epidemic season in Europe (i.e.,
December–March). Figure 1 shows a considerable exposure to
influenza throughout the year, including months when influ-
enza was not prevalent in Switzerland.
Three patients (7.5%) among the 40 who had seroconversion
to influenza virus had to change their itinerary because of ill-
ness, and 16 (40.0%) sought medical attention either abroad
or after returning to Switzerland or both. Thirty-two subjects
(80.0%) with positive HI results felt healthy again at the time
of completion of the survey; the others had mostly minor re-
sidual illness or relapses of influenza-like illness, including fever,
cough, headache, or otitis media.
The sensitivity analysis showed that subjects with confirmed
and probable influenza were comparable and did not differ
significantly with respect to reported symptoms of influenza-
like illness (e.g., subjective fever, temperature of 38.0C, sore
throat, cough, headache, and myalgia), demographic charac-
teristics, and travel characteristics.
Demographic and travel-related variables showed similar dis-
tributions in the subpopulation from whom paired serum sam-
ples were collected and in the whole study population. The only
exception was the Indian subcontinent with regard to travel
destination, which was significantly overrepresented in the sub-
group providing paired serum samples, compared with the
whole study population ( ).P ! .05
DISCUSSION
This cohort study demonstrates that influenza is a frequent
health problem among travelers to subtropical and tropical
countries and that the risk is far from limited to cruises. The
attack rate of 1.2%–2.8% and the monthly incidence of influ-
enza-associated febrile events of 1.0%–2.3% in confirmed and
probable infections, respectively, make this clearly the most
frequent vaccine-preventable infection in travelers to tropical
or subtropical countries. The risk of influenza virus infection
is 3-fold greater than the risk of clinical hepatitis A virus
infection [1]. The impact of influenza is considerable; of all
travelers recruited, 11% required medical attention abroad or
after return, and 0.2% had to change their travel plans. The
distribution of the destinations reflects the travel pattern for
Swiss visitors to subtropical and tropical countries between
1998 and 2000: Asia, 40%; Africa, 35%; and Latin America,
25% [20]. Thus, we believe that we enrolled a representative
sample in that respect.
In the search for particular risk groups, the GeoSentinel sur-
veillance network [13] found travel duration of 130 days to be
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Figure 1. Proportion of influenza virus infections per month of travel, January 1998 to May 2000
a risk factor for influenza virus infection. We were unable to
confirm this finding, possibly because of the small number of
cases detected. We found the Indian subcontinent to be a
higher-risk area.
The WHO rated the investigated 3 influenza seasons as mod-
erate to severe in the Northern Hemisphere, whereas activity
was reported to be less extensive in the Southern Hemisphere.
The majority of infections were reported outside the traditional
influenza epidemic season in the Northern Hemisphere be-
tween December and March (figure 1). We cannot, however,
differentiate whether influenza virus infection occurred just
before departure at home, en route, abroad, or shortly upon
return. For affected travelers, this is presumably of limited rel-
evance, because the impact of influenza may be equally im-
portant whether it infects a traveler just before departure or
upon resumption of normal activities shortly after return.
Because confirmed and probable cases were comparable with
respect to influenza-like symptoms, the 2 groups were subse-
quently combined. Approximately 30% of influenza virus in-
fections remained clinically undetected, and this estimate is
consistent with field studies in which proportions of asymp-
tomatic infections of 15%–42% were reported [21, 22]. Such
persons are also relevant, because they could unwittingly con-
tribute to the spread of influenza. The higher attack rate of
febrile illness compared with that seen in previous surveys
(11%–13%) [5, 23] could be explained by the fact that sur-
veillance was extended for 2 weeks after return.
Eight antigenically distinguishable reference strains were used
to detect infections due to the prevailing influenza A and B
viruses during the study period. The frequency of detection
reflected the relative prevalence of the A (H3N2), A (H1N1),
and B viruses—in particular, the worldwide predominance of
A (H3N2) viruses during January 1998 and March 2000 [24–
26]. The HI assay is the method of choice for epidemiological
surveys of influenza because it is easy to use, it can be performed
late in the course of infection or after recovery, and the de-
termination of the seroconversion rate shows a good specificity
[27, 28]. On the other hand, the accuracy of our results may
be limited by several factors. First, the sensitivity of the labo-
ratory case definition: mixed or multiple infections occurred,
and other infections might have been the origin of fever, re-
sulting in an overestimation of influenza-related fever cases or
an underestimation of afebrile influenza virus infections, re-
spectively. Second, we included subjective fever, because many
subjects do not carry thermometers. We calculated all rates for
the total number of travelers recruited, although only 73% of
the febrile patients had provided second serum samples and
had the chance to be detected by seroconversion; this may have
resulted in an underestimation of the risk of influenza. In ad-
dition, the present 13 asymptomatic influenza cases (4.0%)
were found among only 321 healthy travelers. When referring
to the overall population of 1161 healthy travelers, a total of
47 asymptomatic cases can be estimated.
In conclusion, the importance of influenza in travelers to
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subtropical and tropical countries has thus far been neglected.
Influenza is the most frequent vaccine-preventable infection
among this population, and it has a considerable impact. In-
fluenza vaccination should certainly be recommended to the
traditional at-risk groups, such as senior travelers and those
with various preexisting illnesses, during pretravel health ad-
vice. Beyond those, it should be considered for others who are
willing to take the expense to increase the chance of remaining
healthy while abroad. The most recently licensed influenza vac-
cines, including those for the opposite hemisphere, would need
to be available at least to travel clinics to reduce the risk of
vaccine failure [29, 30]. Alternatively, in cases in which influ-
enza vaccines are unavailable or contraindicated, guidelines for
administering and using antiviral medications should be
established.
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